体积 1, 问题 2 (2011)
治疗前景
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Brian Lam,Zobair M Younossi
评论文章
Diagnosis and treatment of prostate cancer-related bone disease
Tilman Todenhoefer, Georgios Gakis, David Schilling, Gerhard Feil, Christian Schwentner,Arnulf Stenzl
评论文章
Tyrosine kinase inhibitors in differentiated thyroid arcinoma: a review of the clinical evidence
Hendrieke C Hoftijzer, Ellen Kapiteijn2, Tatiana, Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom, Johannes WA Smit
评论文章
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
评论文章
Emerging treatments for small-cell lung cancer: Phase II and III trials
Joel W Neal, Matthew A Gubens, Heather A Wakelee
评论文章
Clinical efficacy and safety of moroctocog alfa
Emanuela Marchesini, Domenico Prisco, Alfonso Iorio
评论文章
Velaglucerase alfa in the treatment of Gaucher disease type 1
Thomas A Burrow, Gregory A Grabowski
评论文章
Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program
Javier Rueda, Miguel A Gonzlez-Gay, Ricardo Blanco
评论文章
Eltrombopag for the treatment of chronic immune thrombocytopenia
Stavroula Tsiara, Nichola Cooper
治疗前景
Development of antibiotics for Gram-negatives: where now?
Matteo Bassetti, Francesca Ginocchio, Daniele Roberto, Giacobbe, Malgorzata Mikulska
